Charles Bair

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.

Cooley advised Turning Point Therapeutics on its $191.5 million initial public offering of 10,637,500 shares of common stock. Turning Point Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol “TPTX,” is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Partners Charles Bair and Karen Anderson led the Cooley team.

Cooley advised Allogene Therapeutics, Inc. on its $372.6 million initial public offering of 20,700,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 2,700,000 shares. Partners Charles Bair and Charlie Kim led the Cooley team advising Allogene Therapeutics.

Goldman Sachs, J.P. Morgan Securities, Cowen and Jefferies acted as joint book-running managers for the offering.

Allogene Therapeutics is a clinical stage immuno-oncology company developing allogeneic T cell therapies for the treatment of cancer. The company’s shares now trade on the Nasdaq Global Select Market under the symbol “ALLO.”

Cooley advised Cidara Therapeutics on its initial public offering. Cidara, headquartered in San Diego, is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. The company trades on the Nasdaq Global Market under the symbol "CDTX."